KennethCusiMD
Endocrinology • Gainesville, FLDiabetes, Lipid Metabolism
Professor, Medicine, University of Florida College of Medicine
Dr. Cusi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1600 SW Archer Rd
Gainesville, FL 32610Phone+1 352-273-8661Fax+1 352-846-2231
Education & Training
Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 1989 - 1992
University of Buenos AiresClass of 1984
Certifications & Licensure
FL State Medical License 2011 - 2026
TX State Medical License 1994 - 2016- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FACP) American College of Physicians, 2006
- Fellow (FACE) American Association of Clinical Endocrinology
Clinical Trials
- University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Start of enrollment: 2008 Dec 01
- Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Start of enrollment: 2010 Jun 24
- The Role of Non-Alcoholic Fatty Liver Disease in Gestational Diabetes Start of enrollment: 2013 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease.Jacob J Gries, Jeffrey V Lazarus, Paul N Brennan, Mohammad S Siddiqui, Giovanni Targher
The Lancet. Gastroenterology & Hepatology. 2025-01-01 - 2 citationsResmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.Vincent L Chen, Timothy R Morgan, Yaron Rotman, Heather M Patton, Kenneth Cusi
Hepatology. 2025-01-01 - Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).Mazen Noureddin, Emily Truong, Rebeca Mayo, Ibon Martínez-Arranz, Itziar Mincholé
Hepatology. 2025-01-01
Journal Articles
- Effect of Canagliflozin Treatment on Hepatic Triglyceride Content and Glucose Metabolism in Patients with Type 2 DiabetesDiana Barb, Sunder Mudaliar, Kenneth Cusi, Diabetes, Obesity and Metabolism
Lectures
- Guided Posters: Diabetes and Glucose MetabolismENDO 2019 - New Orleans, LA - 3/24/2019
- Response to Comment on Bril Et Al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care 2018;41:187–192Gainesville, FL - 6/16/2014
- Response to Comment on Bril Et Al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care 2018;41:187–192Gainesville, FL - 6/16/2014
- Join now to see all
Authored Content
- Lecture NASH in Diabetes: Epidemiology and DiagnosisMay 2022
Press Mentions
First Fatty Liver Guidelines for Endocrinology, Primary CareMay 13th, 2022- Hepatic Steatosis Observed in Most Adults with Obesity, DiabetesJanuary 5th, 2022
- Poxel Reports Financial Results for First Half 2021 and Provides a Corporate UpdateSeptember 23rd, 2021
- Join now to see all
Professional Memberships
- Fellow
- Fellow
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
